Navigation Links
Pharma Product Commercialization: Standardized Team Processes Help Save Complex Drug Launches
Date:1/31/2008

CHAPEL HILL, N.C., Jan. 31 /PRNewswire/ -- The new product development process is exceedingly complex. It spans many years, involves multitudes of people, and consumes hundreds of millions of dollars in capital resources. Not surprisingly, one pharmaceutical marketing executive noted: "This process is so complex that no single person in the organization actually knows how all the parts work."

For this reason, benchmark partners emphasize the importance of standardizing the new-product development process while implementing strong cross-functional launch teams. This team's role of shaping the compound into a successful product is just as important as the biological attributes of the compound. With standardization, individuals and teams can better understand where and how to introduce market insights into the long-spanning commercialization process.

The report, "Managing Cross-Functional Teams for Pharmaceutical Product Commercialization Excellence," delivers proven practices that best-in-class firms use to enable and manage effective cross-functional teams, such as empowering launch teams to make key decisions and team members following well- established, standardized processes.

Download a complimentary study summary at http://www3.best-in-class.com/rr906.htm.

Learn from industry leaders, including Amgen, AstraZeneca, Bayer, Eli Lilly GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Wyeth. Executives in pharma and biotech companies can use this research to build and manage strong launch teams that can excel across functions, units and regions.

High-performing systems find many places and methods to introduce standardization into commercialization activities, for example:
-- Conduct strategy meetings to forge consensus between Strategic

Marketing, Decision Analytics, R&D, Regulatory, Finance

-- Model markets for R&D and marketing organizations

-- Prioritize product lists using qualitative and quantitative

methodologies (NPVs, performance criteria scorecards)

-- Conduct therapeutic area-specific CI

-- Develop portfolio valuations that embed commercial perspectives in the

valuation process

-- Provide input for clinical trial design and desired clinical outcomes

-- Conduct product risk analyses

Download additional process excellence tactics and best practices for building successful cross-functional teams in the study summary at: http://www3.best-in-class.com/rr906.htm.

This benchmarking report highlights the following areas of cross- functional team management:
-- Cross-Functional Team Structures

-- Collaboration and Productivity Processes

-- People Management

-- Decision-Making Processes

-- Communication and Collaboration

-- Resource Allocation

For more information contact our Solution Specialists at (919) 403-0251 or bestpractices@best-in-class.com.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for nearly 15 years; our clients include 43 out of the top 50 pharmaceutical companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... ... August 3rd article on Reuters covers a new University of Michigan study on ... of the American Medical Association). The study found that a lower percentage of patients with ... to patients with lower BMIs. At present, weight loss patients must have a BMI of ...
(Date:8/16/2017)... Va. (PRWEB) , ... August 16, 2017 , ... ... America (BIAA) is collaborating with a New England student to educate the public ... to acclaim in 2016 for launching the first-ever National Concussion Awareness Day. , ...
(Date:8/16/2017)... ... , ... Maury Regional Health has announced a large-scale adoption of AccuVein vein ... Maury Regional Medical Center is making vein visualization part of their standard of care. ... more importantly, helps our staff members locate a vein that will provide good access ...
(Date:8/16/2017)... ... August 16, 2017 , ... With a new PD diagnosis every ... cure. , The grants are awarded through a competitive application process and reviewed ... array of backgrounds and expertise in all areas relevant to PD research. The ...
(Date:8/16/2017)... Sacramento, CA (PRWEB) , ... August 16, 2017 ... ... ($10.99, paperback, 9781498499613; $5.99, eBook, 9781498499620    ) shares that during the time of a ... as reminding Strawn of God's love, and all the many ways God shows ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO), has been named one of ... by Crain,s Detroit Business . The annual Crain,s ... revenue growth. This year,s edition measures growth from 2013 to ... complete list, visit crainsdetroit.com/awards/fast_50/2017 .  "Being ... Phil Hagerman , CEO and chairman of Diplomat. "We,ve ...
(Date:7/27/2017)... 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... June 30, 2017.  The Company reported second quarter net ... the prior year period, and an increase of 2.1% ... points of contribution from the LDR Holding Corporation acquisition, ... quarter of 2016, or 0.3% on a constant currency ...
(Date:7/26/2017)... The Galien Foundation announced today the ... Award Nominees. Counted among the global health innovation ... biomedical and technology product achievement that improves the human condition. ... candidate must be U.S. Food and Drug Administration (FDA) approved ... potential to impact human health. Sales data are not considered ...
Breaking Medicine Technology: